title: Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma.
abstract: OBJECT There are few and conflicting reports on the effects of delayed initiation of chemoradiotherapy on the survival of patients with glioblastoma. The standard of care for newly diagnosed glioblastoma is concurrent radiotherapy and temozolomide chemotherapy after maximal safe resection; however, the optimal timing of such therapy is poorly defined. Given the lack of consensus in the literature, the authors performed a retrospective analysis of The Cancer Genome Atlas (TCGA) database to investigate the effect of time from surgery to initiation of therapy on survival in newly diagnosed glioblastoma. METHODS Patients with primary glioblastoma diagnosed since 2005 and treated according to the standard of care were identified from TCGA database. Kaplan-Meier and multivariate Cox regression analyses were used to compare overall survival (OS) and progression-free survival (PFS) between groups stratified by postoperative delay to initiation of radiation treatment. RESULTS There were 218 patients with newly diagnosed glioblastoma with known time to initiation of radiotherapy identified in the database. The median duration until therapy was 27 days. Delay to radiotherapy longer than the median was not associated with worse PFS (HR = 0.918, p = 0.680) or OS (HR = 1.135, p = 0.595) in multivariate analysis when controlling for age, sex, KPS score, and adjuvant chemotherapy. Patients in the highest and lowest quartiles for delay to therapy (≤ 20 days vs ≥ 36 days) did not statistically differ in PFS (p = 0.667) or OS (p = 0.124). The small subset of patients with particularly long delays (> 42 days) demonstrated worse OS (HR = 1.835, p = 0.019), but not PFS (p = 0.74). CONCLUSIONS Modest delay in initiation of postoperative chemotherapy and radiation does not appear to be associated with worse PFS or OS in patients with newly diagnosed glioblastoma, while significant delay longer than 6 weeks may be associated with worse OS.
authors.affiliation: Department of Neurological Surgery, University of California, San Francisco, California; and.
authors.forename: Matthew Z
authors.initials: MZ
authors.lastname: Sun
authors.forename: Taemin
authors.initials: T
authors.lastname: Oh
authors.forename: Michael E
authors.initials: ME
authors.lastname: Ivan
authors.forename: Aaron J
authors.initials: AJ
authors.lastname: Clark
authors.forename: Michael
authors.initials: M
authors.lastname: Safaee
authors.forename: Eli T
authors.initials: ET
authors.lastname: Sayegh
authors.forename: Gurvinder
authors.initials: G
authors.lastname: Kaur
authors.forename: Andrew T
authors.initials: AT
authors.lastname: Parsa
authors.forename: Orin
authors.initials: O
authors.lastname: Bloch
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D059248:Chemoradiotherapy; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000401:mortality* / Q000601:surgery / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D061665:Time-to-Treatment; D055815:Young Adult
keywords: CI = confidence interval; HR = hazard ratio; KPS = Karnofsky Performance Scale; OS = overall survival; PFS = progression-free survival; TCGA = The Cancer Genome Atlas; The Cancer Genome Atlas; glioblastoma; oncology; overall survival; progression-free survival; treatment delay